CEPROTIN

Product Specs	CEPROTIN
Manufacturer Name	Takeda
Indications	For pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
Contraindications	None known
Manufacturing Methods	Protein C is the precursor of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulincomplex on the endothelial cell surface to activated Protein C (APC). APC is a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S.
Viral Safety Process	Combination of filtration and chromatographic procedures including a column of immobilized mouse monoclonal antibodies on gel beads
Route of Administration	May be administered intravenously via sterile syringe or via an infusion bag
Product Half-Life	Initial Half-Life: 5.4 to 9.3 hours Terminal Half-Life: 7.0 to 12.4 hours
Storage Requirements/Shelf Life	Refrigerate between 2°C and 8°C (36-46°F) for up to 3 years. Do not freeze in order to prevent damage to the diluent vial. Store the vial in the original carton to protect it from light. The reconstituted solution should be used within 3 hours of reconstitution. Do not use beyond the expiration date.
Available Formulations	500 IU/5 mL 1000 IU/10 mL